<DOC>
	<DOCNO>NCT02248467</DOCNO>
	<brief_summary>The primary purpose study evaluate , obese hypogonadal patient eligible bariatric surgery , effect testosterone replacement therapy improve low urinary tract symptom ( LUTS ) assess use IPSS ( International Prostate Symptom Score ) questionnaire , compare hypogonadal untreated subject eugonadal subject .</brief_summary>
	<brief_title>Study Effect Testosterone Treatment Metabolic Parameters Urinary Symptoms Bariatric Patients</brief_title>
	<detailed_description>Primary objective : - Evaluation obese hypogonadal patient candidate bariatric surgery effect testosterone replacement therapy improve symptom LUTS ( assess use IPSS questionnaire ) compare hypogonadal untreated subject eugonadal subject . Secondary objective : - Evaluation effect testosterone obese hypogonadal patient candidate bariatric surgery improve metabolic parameter ( glycaemia , oral glucose tolerance test , HbA1c , total cholesterol , HDL cholesterol , triglyceride , arterial pressure , BMI , waist circumference ) compare hypogonadal untreated subject eugonadal subject - Evaluation effect testosterone obese hypogonadal patient candidate bariatric surgery improve uroflowmetric parameter compare hypogonadal untreated subject eugonadal subject - Evaluation effect testosterone obese hypogonadal patient candidate bariatric surgery ultrasound characteristic prostate ( macro-calcifications , intraprostatic arterial velocity , volume prostate gland ) . - Evaluation effect testosterone obese hypogonadal patient candidate bariatric surgery pre-adipocytes isolated visceral adipose tissue sample collect surgical procedure , compare hypogonadal untreated subject eugonadal subject .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male subject Age 25 65 year Obese men , candidate bariatric surgery ( body mass index ( BMI ) ≥40 kg/m2 , BMI &gt; 35 kg/m2 suffer lifethreatening comorbidities Type 2 Diabetes Mellitus , hypertension cardiovascular disease ) Men LUTS define : IPSS ≥ 8 . Evidence personally sign date informed consent Bladder failure Neurogenic bladder LUT disease ( Urethral stenosis , diverticulum ) LUT surgery ( Prostatectomy , bladder neck surgery , TURP ) Severe systemic disease Previous concomitant neoplasm Unable consistently accurately complete protocol Abuse alcohol drug Psychiatric disease</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Testosterone replacement therapy</keyword>
</DOC>